Carolacton and derivatives thereof for use in the treatment of cell proliferation disorders

US11357752B2 · kind B2 · utility

Assignee

• Helmholtz-Zentrum Für Infektionsforschung GmbH · DE

Inventors

• Chengzhang Fu · Riegelsberg, DE
• Rolf Muller · Marburg, DE
• Jannik Donner · Stadthagen, DE
• Michael E. Reck · Worcester, US
• Irene Wagner-Dobler · Evessen, DE
• Andreas Kirschning · Celle, DE
• Jonas Ammermann · Hannöver, DE

Key dates

• Filing date: Jun 1, 2018
• Grant date: Jun 14, 2022
• Expiry date: Jun 1, 2038

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Chemical compounds are provided that are useful in the treatment of diseases associated with an activity of a 5,10-methylenyltetrahydrofolate cyclohydrolase/5,10-methylene tetrahydrofolate dehydrogenase enzyme in pathological eukaryotic cells. In particular, compounds that exhibit inhibitory activity upon 5,10-methylenyltetrahydrofolate cyclohydrolase/5,10-methylene tetrahydrofolate dehydrogenase enzymes and their use in the treatment of cancer and/or parasitic diseases are provided.